AIM ImmunoTech Raises $2.4 Million via 7.52 M Shares and 15 M Series I Warrants
AIM ImmunoTech will sell 7.52 million common shares at $0.325 each in a registered direct offering to raise $2.4 million before fees. It issued Series I warrants for 15.04 million shares at a $0.325 exercise price, exercisable for five years to fund clinical supply, Phase 3 trials and working capital.
1. Registered Direct Offering Terms
The company executed a registered direct offering priced at the market under NYSE rules, issuing 7,519,351 common shares at $0.325 per share for gross proceeds of approximately $2.4 million before placement agent fees and expenses. The offering is expected to close on or about May 21, 2026, subject to customary closing conditions.
2. Series I Warrants Structure
Concurrently, AIM ImmunoTech placed unregistered Series I warrants entitling holders to purchase up to 15,038,702 shares at a $0.325 exercise price. These warrants will become exercisable upon stockholder approval and expire five years from the initial exercise date.
3. Intended Use of Proceeds
Net proceeds from the offering will be allocated toward manufacturing clinical drug supply, advancing planned Phase 3 clinical trial activities for Ampligen®, and general working capital purposes to support ongoing immuno-pharma research and development efforts.